{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(3)"],"submitter":["Bloom PP"],"pubmed_abstract":["<h4>Background</h4>Novel therapies are needed to treat HE, and microbiome modulation is a promising target. VE303 is a defined consortium of 8 purified, clonal bacterial strains, known to produce metabolites that may be beneficial in HE. We evaluated the safety and efficacy of VE303 to treat HE.<h4>Methods</h4>We performed a single-center, randomized, placebo-controlled trial of VE303 in adult patients with a history of overt HE (NCT04899115). Eligible patients were taking lactulose and rifaximin, had no recent systemic antibiotics, and had MELD ≤20. All patients received 5 days of oral vancomycin followed by randomization to 14 days of VE303 or placebo (2:1). The primary endpoints were incidence of serious adverse events and change in psychometric HE score (PHES) from baseline to 4 weeks "],"journal":["Hepatology communications"],"pagination":["e0650"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11841841"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of a defined bacterial consortium, VE303, to treat HE."],"pmcid":["PMC11841841"],"pubmed_authors":["Silber JL","Crossette E","Young VB","Norman JM","Lok ASF","Bloom PP","Bassis CM"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of a defined bacterial consortium, VE303, to treat HE.","description":"<h4>Background</h4>Novel therapies are needed to treat HE, and microbiome modulation is a promising target. VE303 is a defined consortium of 8 purified, clonal bacterial strains, known to produce metabolites that may be beneficial in HE. We evaluated the safety and efficacy of VE303 to treat HE.<h4>Methods</h4>We performed a single-center, randomized, placebo-controlled trial of VE303 in adult patients with a history of overt HE (NCT04899115). Eligible patients were taking lactulose and rifaximin, had no recent systemic antibiotics, and had MELD ≤20. All patients received 5 days of oral vancomycin followed by randomization to 14 days of VE303 or placebo (2:1). The primary endpoints were incidence of serious adverse events and change in psychometric HE score (PHES) from baseline to 4 weeks ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-06T23:32:23.914Z","creation":"2026-06-06T03:10:55.497Z"},"accession":"S-EPMC11841841","cross_references":{"pubmed":["39969428"],"doi":["10.1097/HC9.0000000000000650"]}}